drugset / Trial / NCT03664180
Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI
Phase 4
Completed
2989 enrolled
Beijing Anzhen Hospital
Chinese Academy of Medical Sciences, Fuwai Hospital · collabGroupe Hospitalier Pitie-Salpetriere · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The RIGHT study is a large randomized study dedicated to post-PPCI anticoagulation in STEMI patients. The investigators propose to evaluate the clinical efficacy and safety of anticoagulation prolonged for at least 48 hours after the procedure vs. no prolongation of anticoagulation after procedure in patients with STEMI treated with bivalirudin during PPCI (primary hypothesis). When allocated to anticoagulation prolongation by randomization, the subject will be assigned to UFH, enoxaparin or bivalirudin (same regimen allocated by centre) for at least 48 hours after PPCI. The results from this study are expected to provide guidance on the risk/benefit of post-procedural anticoagulation in patients with STEMI.
Timeline
- Start
- 2019-01-11
- Primary completion
- 2022-11-23
- Completion
- 2022-11-23
Publications
- Background Yan Y, Wang X, Guo J, Li Y, Ai H, Gong W, Que B, Zhen L, Lu J, Ma C, Montalescot G, Nie S. Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am Heart J. 2020 Sep;227:19-30. doi: 10.1016/j.ahj.2020.06.005. Epub 2020 Jun 20.
- Yan Y, Wang X, Fan Z, Guo J, Wang G, Yin D, Wang Z, Zhang F, Tian C, Gong W, Liu J, Lu J, Ma C, Vicaut E, Montalescot G, Nie S; RIGHT Investigators. Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention: 1-Year Results From the RIGHT Trial and Meta-analyses. JACC Asia. 2026 May 13:S2772-3747(26)00251-6. doi: 10.1016/j.jacasi.2026.04.003. Online ahead of print.
- Yan Y, Guo J, Wang X, Wang G, Fan Z, Yin D, Wang Z, Zhang F, Tian C, Gong W, Liu J, Lu J, Li Y, Ma C, Vicaut E, Montalescot G, Nie S; RIGHT Investigators. Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial. Circulation. 2024 Apr 16;149(16):1258-1267. doi: 10.1161/CIRCULATIONAHA.123.067079. Epub 2024 Feb 26.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bivalirudin | Peptide | 0.2 mg/kg | Intravenous |
| Subject | Enoxaparin sodium | Other / unclassified | 40 mg | Subcutaneous |
| Subject | Heparin | Other / unclassified | 10 iu/kg | Intravenous |